25017-89-4Relevant articles and documents
In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor
Schmidt, Jonathan M.,Tremblay, Gilles B.,Plastina, Michael A.,Ma, Fupeng,Bhal, Sanjivanjit,Feher, Miklos,Dunn-Dufault, Robert,Redden, Peter R.
, p. 1819 - 1828 (2008/02/02)
There is still a need for additional scaffolds to further explore tissue selectivity and improving efficacy of selective estrogen receptor modulators (SERMs). A series of hydroxyl substituted diphenylnaphthyl alkene ligands for the two estrogen receptors are described that arose from an initial de novo designed diphenylnaphthyl propylene ligand 1. All compounds gave Kis under 10 nM when assayed in the presence of ERα. Generally these compounds had very high affinity for both ER isotypes. Moving the hydroxyl group on naphthalene from the 6- to the 5-position of the α-naphthalene attached compounds (6b and 6e vs 6c and 6f) had little affect on ER binding nor did altering the position of the naphthalene attachment (α or β) to the alkene moiety. In transfection assays none of the compounds displayed agonistic activity in the absence of E2. In MCF-7 proliferation assays 6a-d, 6f and 12a-c successfully abrogated E2 stimulation and resulted in greater than 50% inhibition at 1 μM, a level of efficacy similar to that obtained when the cells were treated with raloxifene. Our results show that this new class of SERMs are good candidates for further study as therapeutic agents for the treatment of breast cancer and osteoporosis.
1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof
-
, (2008/06/13)
Molecules demonstrating anti-proliferative effects against epithelial cancer cell lines, human estrogen-dependent cancer cells and endothelial cells are disclosed. The molecules are intended for use in therapeutic preparations for the treatment of various
